TY  - JOUR
AU  - Svačina, Martin K. R.
AU  - Sprenger-Svačina, Alina
AU  - Tsakmaklis, Anastasia
AU  - Rüb, Alina M.
AU  - Klein, Ines
AU  - Wüstenberg, Hauke
AU  - Fink, Gereon R.
AU  - Lehmann, Helmar C.
AU  - Vehreschild, Maria J. G. T.
AU  - Farowski, Fedja
TI  - The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy
JO  - European journal of neurology
VL  - 30
IS  - 11
SN  - 1351-5101
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell
M1  - FZJ-2023-01611
SP  - 3551-3556
PY  - 2023
AB  - AbstractBackground and purpose: The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking.Methods: In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female).Results: The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95).Conclusions: The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP.Keywords: autoimmunity; firmicutes; immune neuropathies; intestinal barrier; short-chain fatty acids (SCFA).
LB  - PUB:(DE-HGF)16
C6  - 36651357
UR  - <Go to ISI:>//WOS:000925036100001
DO  - DOI:10.1111/ene.15679
UR  - https://juser.fz-juelich.de/record/1005757
ER  -